Second annual report from the ISSPP PIPAC database
Pleura and Peritoneum · 22.12.2023 · 8 (4) · 141-146
DOI: 10.1515/pp-2023-0047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pleura and Peritoneum, online erschienen am 13.12.2023. Verfasst von Michael Bau Mortensen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Upper GI and HPB Section, Department of Surgery, Odense Universitetshospital, Odense, Denmark. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
To monitor the results of PIPAC directed therapy based on data from the International Society for the Study of the Pleura and Peritoneum (ISSPP) PIPAC database.
Methods
Analysis of data from patients entered between June 15th, 2020, and February 28th, 2023.
Results
Twelve centers reported 2,456 PIPAC procedures in 809 patients (median 2, range 1–18) with peritoneal metastasis (PM) from different primary tumors. Approximately 90 % had systemic chemotherapy prior to PIPAC. Twenty-eight percent were treated in prospective protocols. Overall non-access rate was 3.5 %. Concomitant surgical procedures were performed during PIPAC in 1.6 % of the patients. Median length of stay was 2 days. A total of 95 surgical complications were recorded, but only 22 % of these were graded ≥3b. Seventeen-hundred-and-three adverse events were noted, and 8 % were classified ≥3. The rate of complete or major histological response (peritoneal regression grade score, PRGS≤2) increased between the first and the third PIPAC in the group of patients who were evaluated by PRGS, and a PRGS ≤2 or a reduction of the mean PRGS of at least 1 between first and third PIPAC were observed in 80 %. Disease progression (50 %) or technical issues (19 %) were the most important reasons for stopping PIPAC treatment. Median overall survival from first PIPAC directed treatment varied from 10.7 months (CI 8.7–12.5) in gastric cancer to 27.1 months (16.4–50.5) in mesothelioma.
Conclusions
The ISSPP PIPAC database provides substantial real-world data supporting the use of PIPAC directed therapy in patients with PM from different primary tumors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Upper GI and HPB Section, Department of Surgery, Odense Universitetshospital, Odense, Denmark.
- General and Upper GI Surgery, University of Verona, Verona, Veneto, Italy.
- Department of Surgical Oncology, İstanbul Ümraniye Training and Research Hospital, Istanbul, Türkiye.
- Service de Chirurgie Digestive et Oncologique, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France.
- Department of Surgery, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia.
- Lausanne University Hospital CHUV, University of Lausanne, Lausanne, Switzerland.
ORCID-Profile: Michael Bau Mortensen, Marc Pocard
Zitieren
APA
Mortensen, M. B., Casella, F., Düzgün, Ö., Glehen, O., Hewett, P., Hübner, M., Jørgensen, M. S., Königsrainer, A., Marin, M., Pocard, M., Rezniczek, G., So, J., & Fristrup, C. W. (2023). Second annual report from the ISSPP PIPAC database. Pleura and Peritoneum, 8(4), 141-146. https://doi.org/10.1515/pp-2023-0047
Vancouver
Mortensen MB, Casella F, Düzgün Ö, Glehen O, Hewett P, Hübner M, et al. Second annual report from the ISSPP PIPAC database. Pleura and Peritoneum. 2023;8(4):141-146. doi:10.1515/pp-2023-0047
BibTeX
@article{Mortensen2023,
author = {Mortensen, Michael Bau and Casella, Francesco and Düzgün, Özgül and Glehen, Olivier and Hewett, Peter and Hübner, Martin and Jørgensen, Magnus Skov and Königsrainer, Alfred and Marin, Miguel and Pocard, Marc and Rezniczek, Günther and So, Jimmy and Fristrup, Claus Wilki},
title = {Second annual report from the ISSPP PIPAC database},
journal = {Pleura and Peritoneum},
year = {2023},
volume = {8},
number = {4},
pages = {141--146},
doi = {10.1515/pp-2023-0047}
}
EUVIMED